- Home
- RLAY vs MIST Comparison
RLAY vs MIST Comparison
Compare RLAY & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLAY | MIST |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 176.3M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | RLAY | MIST |
|---|---|---|
| Price | $14.54 | $1.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $19.50 | $8.00 |
| AVG Volume (30 Days) | ★ 4.3M | 1.4M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,355,000.00 | N/A |
| Revenue This Year | N/A | $2,915.14 |
| Revenue Next Year | $324.03 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 53.44 | N/A |
| 52 Week Low | $2.98 | $1.00 |
| 52 Week High | $17.47 | $3.06 |
Technical Indicators
Market Signals| Indicator | RLAY | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 56.61 | 29.54 |
| Support Level | $11.68 | $1.00 |
| Resistance Level | $15.45 | $2.30 |
| Average True Range (ATR) | 1.16 | 0.08 |
| MACD | 0.20 | -0.02 |
| Stochastic Oscillator | 50.43 | 5.88 |
Price Performance
Historical ComparisonAbout RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).